| scholarly article | Q13442814 |
| P2093 | author name string | Chang-Sheng Deng | |
| Dong-Zhou Liu | |||
| Li-Hong Xu | |||
| Shi-Quan Liu | |||
| You-Qing Zhu | |||
| P2860 | cites work | TRAIL: a molecule with multiple receptors and control mechanisms | Q77485552 |
| Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter | Q78632796 | ||
| TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. | Q24314730 | ||
| Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family | Q24315643 | ||
| The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain | Q24320162 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| A novel receptor for Apo2L/TRAIL contains a truncated death domain | Q28255451 | ||
| TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB | Q28259095 | ||
| TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling | Q28267294 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Chemotherapy augments TRAIL-induced apoptosis in breast cell lines | Q34756715 | ||
| Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87 | Q36397251 | ||
| Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines | Q38358514 | ||
| Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. | Q39700468 | ||
| Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma | Q40605148 | ||
| Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities | Q40653393 | ||
| Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation | Q40677992 | ||
| Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death | Q40705443 | ||
| Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs | Q40762117 | ||
| p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. | Q40897440 | ||
| The abnormal expression of retinoic acid receptor-beta, p 53 and Ki67 protein in normal, premalignant and malignant esophageal tissues. | Q42283339 | ||
| Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines | Q43159614 | ||
| Sensitization of human colon cancer cells to TRAIL-mediated apoptosis | Q43579921 | ||
| Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil | Q43828854 | ||
| Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro | Q44094743 | ||
| Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines | Q44122252 | ||
| Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. | Q44215095 | ||
| Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance | Q44215252 | ||
| Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression | Q45857333 | ||
| Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. | Q53950070 | ||
| Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. | Q54033702 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. | Q54066499 | ||
| Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells | Q73075587 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| colon cancer | Q18555025 | ||
| cancer cell line | Q23058136 | ||
| P304 | page(s) | 1241-1245 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. | |
| P478 | volume | 9 |
| Q36496451 | Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. |
| Q54111806 | Kaempferol Induces G2/M Cell Cycle Arrest via Checkpoint Kinase 2 and Promotes Apoptosis via Death Receptors in Human Ovarian Carcinoma A2780/CP70 Cells. |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q81086247 | Topoisomerase II inhibitors |
| Q33386275 | Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation |
Search more.